Merck receives Idvynso FDA approval for its once-daily single-tablet regimen of doravirine and islatravir. This breakthrough treatment offers a new option for adults living with HIV-1 who are virologically suppressed.
Sanofi has achieved a historic breakthrough with the expanded Tzield FDA approval for young children. Previously restricted to those aged eight and older, the therapy is now available for children as young as one year old, offering a vital window to delay the onset of clinical Type 1 Diabetes.
Indian health officials have intercepted a shipment of suspected counterfeit weight-loss medication. The discovery of fake Mounjaro pens underscores a growing global trend of illicit medical supplies entering the market through online platforms like Alibaba.
Roche announces positive top-line Enspryng Phase III results from the METEOROID study, demonstrating a significant delay in relapses for patients with MOGAD.
Pfizer and Merck announce that the FDA has accepted a supplemental Biologics License Application (sBLA) for PADCEV in combination with KEYTRUDA for Priority Review in patients with muscle-invasive bladder cancer (MIBC).
AstraZeneca has announced that the Phase III MIRANDA trial for tozorakimab successfully met its primary endpoint, marking the third positive pivotal study for the IL-33-targeting biologic in patients with COPD.
Abbott (NYSE: ABT) has released its first-quarter 2026 financial results, showcasing strong organic growth and the strategic integration of Exact Sciences into its world-leading diagnostics portfolio.
Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
GSK has finalized its $950 million acquisition of 35Pharma Inc., securing HS235 a potential best-in-class treatment for pulmonary hypertension with unique metabolic benefits.
India is transitioning from a global manufacturing hub to a leader in deeptech innovation. In this featured interview, Dr. Jogin Desai, CEO of Eyestem, explores how a compressed therapy timeline, the ₹10,000 crore Biopharma SHAKTI programme, and a focus on “reversing” rather than just “slowing” diseases are positioning India to deliver life-changing medical solutions to the world at a fraction of the traditional cost.
